Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Zironi

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinomaG Cocconi, P Carlini, A Gamboni, et al.
British Journal of Cancer|March 10, 2011
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancerF Bertolini, N Malavasi, L Scarabelli, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinomaG Cocconi, P Carlini, A Gamboni, et al.
British Journal of Cancer|March 10, 2011
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancerF Bertolini, N Malavasi, L Scarabelli, et al.
Pageof 2